Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

IGM Biosciences

DB:1K0
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1K0
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

IGM Biosciences, Inc., a biotechnology company, engages in the research and development of engineered Immunoglobulin M (IgM) antibodies for the treatment of cancer patients. The last earnings update was 14 days ago. More info.


Add to Portfolio Compare Print
  • IGM Biosciences has significant price volatility in the past 3 months.
1K0 Share Price and Events
7 Day Returns
10.7%
DB:1K0
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-
DB:1K0
-7.4%
DE Biotechs
-14.2%
DE Market
1K0 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
IGM Biosciences (1K0) 10.7% 9.3% 64% - - -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • No trading data on 1K0.
  • No trading data on 1K0.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is IGM Biosciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for IGM Biosciences. This is due to cash flow or dividend data being unavailable. The share price is €50.5.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for IGM Biosciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are IGM Biosciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1K0 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-4.80
NasdaqGS:IGMS Share Price ** NasdaqGS (2020-04-08) in USD $59.91
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of IGM Biosciences.

DB:1K0 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:IGMS Share Price ÷ EPS (both in USD)

= 59.91 ÷ -4.80

-12.49x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IGM Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.
  • IGM Biosciences is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does IGM Biosciences's expected growth come at a high price?
Raw Data
DB:1K0 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.49x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-12.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for IGM Biosciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on IGM Biosciences's assets?
Raw Data
DB:1K0 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $7.88
NasdaqGS:IGMS Share Price * NasdaqGS (2020-04-08) in USD $59.91
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:1K0 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:IGMS Share Price ÷ Book Value per Share (both in USD)

= 59.91 ÷ 7.88

7.6x

* Primary Listing of IGM Biosciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • IGM Biosciences is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess IGM Biosciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. IGM Biosciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is IGM Biosciences expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-12.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is IGM Biosciences expected to grow at an attractive rate?
  • Unable to compare IGM Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare IGM Biosciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare IGM Biosciences's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:1K0 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1K0 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -12.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1K0 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1K0 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 189 -101 -97 3
2023-12-31 77 18 -123 3
2022-12-31 0 -86 -134 3
2021-12-31 0 -72 -109 4
2020-12-31 0 -50 -81 4
2020-04-09
DB:1K0 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -45 -43
2019-09-30 -39 -37
2019-06-30 -30 -34
2019-03-31 -25 -28
2018-12-31 -20 -23
2017-12-31 -10 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • IGM Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if IGM Biosciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1K0 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from IGM Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1K0 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -2.44 -1.38 -3.49 2.00
2023-12-31 -3.11 -2.01 -4.20 2.00
2022-12-31 -4.11 -3.95 -4.26 2.00
2021-12-31 -3.18 -2.54 -3.73 4.00
2020-12-31 -2.63 -2.48 -2.75 3.00
2020-04-09
DB:1K0 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -4.80
2019-09-30 -26.20
2019-06-30 -71.75
2019-03-31 -62.15
2018-12-31 -51.84
2017-12-31 -25.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if IGM Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess IGM Biosciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
IGM Biosciences has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has IGM Biosciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare IGM Biosciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • IGM Biosciences does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare IGM Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare IGM Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
IGM Biosciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from IGM Biosciences Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1K0 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -43.13 9.24 12.61
2019-09-30 -37.37 7.30 10.93
2019-06-30 -33.72 6.28 14.45
2019-03-31 -28.21 5.05 10.33
2018-12-31 -22.71 3.83 6.21
2017-12-31 -11.05 2.51 4.24

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if IGM Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if IGM Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if IGM Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess IGM Biosciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
IGM Biosciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is IGM Biosciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up IGM Biosciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • IGM Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • IGM Biosciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of IGM Biosciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • IGM Biosciences has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from IGM Biosciences Company Filings, last reported 3 months ago.

DB:1K0 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 240.23 0.00 224.63
2019-09-30 254.62 0.00 242.08
2019-06-30 41.82 0.30 42.67
2019-03-31 41.82 0.30 42.67
2018-12-31 -4.91 5.03 1.89
2017-12-31 0.28 0.00 0.43
  • IGM Biosciences has no debt.
  • IGM Biosciences currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • IGM Biosciences has sufficient cash runway for more than 3 years based on current free cash flow.
  • IGM Biosciences has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 61.5% each year.
X
Financial health checks
We assess IGM Biosciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. IGM Biosciences has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is IGM Biosciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from IGM Biosciences dividends.
If you bought €2,000 of IGM Biosciences shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate IGM Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate IGM Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1K0 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1K0 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-09

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as IGM Biosciences has not reported any payouts.
  • Unable to verify if IGM Biosciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of IGM Biosciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as IGM Biosciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess IGM Biosciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can IGM Biosciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. IGM Biosciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of IGM Biosciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Fred Schwarzer
COMPENSATION $519,214
AGE 66
TENURE AS CEO 9.8 years
CEO Bio

Mr. Fred M. Schwarzer, J.D., was a Founder of Charter Life Sciences, a venture capital firm specializing in life sciences investments, in 2003 and served as its Managing Partner from inception until August 2019. He is a Managing Partner of Charter Life Sciences. Mr. Schwarzer previously served as Chair of the Board of Directors of Inviragen, a biopharmaceutical company and developer of the DENVax dengue vaccine, from 2009 until Inviragen’s acquisition by Takeda Pharmaceutical Company in 2013. Mr. Schwarzer has been the Chief Executive Officer and Chairman of Heska (HSKA) a biotechnology company focused primarily on the animal healthcare markets, from 1994 to 1998 and 1999 to 2001, respectively. He served as Chief Executive Officer and President of Heska Corporation. During his tenure at Heska, Mr. Schwarzer completed corporate Partnerships with Bayer and Novartis, completed seven acquisitions, company’s initial public offering (CSFB and Merrill Lynch), and follow-on public offering (Merrill Lynch, CSFB and H&Q). He served as the President and Chief Executive Officer of Mingly Capital Corporation. Mr. Schwarzer served as an Executive Director of The Mingly Corporation limited (previously listed on the Hong Kong Stock Exchange) and a Senior Vice President of C.M. Capital Corporation. Prior to joining Heska, he was an attorney representing technology companies and venture capitalists. In 1985, Mr. Schwarzer served as a Partner with Pillsbury, Madison & Sutro (now Pillsbury, Winthrop). In 1988, he founded General Counsel Associates (now GCA Law Partners). Mr. Schwarzer also serves as a Director of APT Pharmaceuticals, Inc. since July 21, 2005 and the Chairman of Amaranth Medical, Inc. He has been the Chairman of Kereos, Inc. since March 2009. He served as Chairman of the Board at Visioneering technologies, Inc until December 31, 2019 and serves as Chairman of Minimally Invasive Devices. He served as the Chairman of Palingen, Inc. and Inviragen, Inc. Mr. Schwarzer has extensive operational and fundraising experience, including the development of corporate Partnerships and the structuring of venture capital investments and acquisitions. He has been Director of Kereos, Inc. since 2007. Mr. Schwarzer received a B.A. in Pre-Legal Studies from the University of Michigan and a J.D. from the University of California at Berkeley’s Boalt Hall School of Law. He has served as Chief Executive Officer since July 2010 and has been a Member of Board of Directors since February 2003, serving as Chairman until August 2018 and previously served as Chief Executive Officer and President at different times between December 1999 and May 2003. Mr. Schwarzer has also served as President since December 2018 at IGM Biosciences Inc., formerly known as Palingen, Inc. He served as Director at Visioneering technologies, Inc since November 25, 2008 until December 31, 2019.

CEO Compensation
  • Insufficient data for Fred to compare compensation growth.
  • Fred's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the IGM Biosciences management team in years:

1.7
Average Tenure
56
Average Age
  • The average tenure for the IGM Biosciences management team is less than 2 years, this suggests a new team.
Management Team

Fred Schwarzer

TITLE
CEO, President & Director
COMPENSATION
$519K
AGE
66
TENURE
9.8 yrs

Bruce Keyt

TITLE
Chief Scientific Officer
COMPENSATION
$352K
AGE
66
TENURE
7.7 yrs

Daniel Chen

TITLE
Chief Medical Officer
COMPENSATION
$716K
AGE
49
TENURE
1.7 yrs

Misbah Tahir

TITLE
Chief Financial Officer
AGE
44
TENURE
1.3 yrs

Suzette Tauber

TITLE
Vice President of Human Resources
AGE
56
TENURE
0.8 yrs

Angus Sinclair

TITLE
Vice President of Immuno-Oncology
Board of Directors Tenure

Average tenure and age of the IGM Biosciences board of directors in years:

1.7
Average Tenure
61
Average Age
  • The average tenure for the IGM Biosciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Michael Loberg

TITLE
Chairman of the Board
COMPENSATION
$30K
AGE
71
TENURE
1.7 yrs

Fred Schwarzer

TITLE
CEO, President & Director
COMPENSATION
$519K
AGE
66
TENURE
17.2 yrs

Christina Topsøe

TITLE
Independent Director
AGE
38
TENURE
1.7 yrs

M. Behrens

TITLE
Independent Director
AGE
67
TENURE
1.3 yrs

Julie Hambleton

TITLE
Independent Director
COMPENSATION
$29K
AGE
61
TENURE
1.7 yrs

Jakob Topsøe

TITLE
Independent Director
AGE
50
TENURE
1.7 yrs

Kelvin Neu

TITLE
Independent Director
AGE
46
TENURE
0.8 yrs

William Strohl

TITLE
Independent Director
COMPENSATION
$29K
AGE
67
TENURE
1.7 yrs

Michael Lee

TITLE
Independent Director
AGE
39
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
11. Dec 19 Buy M. Behrens Individual 09. Dec 19 09. Dec 19 20,000 €23.13 €449,176
27. Sep 19 Buy Jakob Topsøe Individual 24. Sep 19 24. Sep 19 4,000 €18.63 €74,524
24. Sep 19 Buy Jakob Topsøe Individual 19. Sep 19 19. Sep 19 14,340 €19.92 €285,596
21. Sep 19 Buy Jakob Topsøe Individual 18. Sep 19 18. Sep 19 34,375 €14.46 €497,145
24. Sep 19 Buy Jakob Topsøe Individual 18. Sep 19 18. Sep 19 1,700 €17.66 €30,020
21. Sep 19 Buy Michael Loberg Individual 18. Sep 19 18. Sep 19 5,000 €16.79 €83,942
20. Sep 19 Buy Baker Bros. Advisors LP Company 20. Sep 19 20. Sep 19 3,144,000 €14.54 €45,721,306
21. Sep 19 Buy Julie Hambleton Individual 18. Sep 19 18. Sep 19 5,000 €16.55 €82,752
21. Sep 19 Buy M. Behrens Individual 18. Sep 19 18. Sep 19 62,500 €14.46 €903,900
20. Sep 19 Buy Haldor Topsøe Holding A/S Company 18. Sep 19 18. Sep 19 1,250,000 €14.46 €18,078,000
20. Sep 19 Buy Christina Topsøe Individual 18. Sep 19 18. Sep 19 34,375 €14.46 €497,145
X
Management checks
We assess IGM Biosciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. IGM Biosciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

IGM Biosciences, Inc., a biotechnology company, engages in the research and development of engineered Immunoglobulin M (IgM) antibodies for the treatment of cancer patients. The company’s lead product candidate is IGM-2323, a bispecific T cell engaging IgM antibody that completed preclinical trials for targeting CD20 and CD3 proteins for the treatment of relapsed/refractory B cell Non-Hodgkin’s lymphoma. It also focuses on developing Death Receptor 5 proteins for the treatment of patients with solid and hematologic malignancies; and T cell engagers, receptor cross-linking agonists, and targeted cytokines. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Details
Name: IGM Biosciences, Inc.
1K0
Exchange: DB
Founded: 1993
$1,683,609,073
30,559,270
Website: http://igmbio.com
Address: IGM Biosciences, Inc.
325 East Middlefield Road,
Mountain View,
California, 94043,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS IGMS Common Stock Nasdaq Global Select US USD 18. Sep 2019
DB 1K0 Common Stock Deutsche Boerse AG DE EUR 18. Sep 2019
Number of employees
Current staff
Staff numbers
64
IGM Biosciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/09 01:01
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/27
Last earnings filing: 2020/03/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.